Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

The recent arrival of CDK4/6 inhibitor agents, with an approximate doubling of progression-free survival (PFS) associated with their use in hormone receptor-positive, HER2-negative advanced breast cancer (BC), has radically changed the approach to managing this disease. However, resistance to CDK4/6...

Full description

Bibliographic Details
Main Authors: Amelia McCartney, Ilenia Migliaccio, Martina Bonechi, Chiara Biagioni, Dario Romagnoli, Francesca De Luca, Francesca Galardi, Emanuela Risi, Irene De Santo, Matteo Benelli, Luca Malorni, Angelo Di Leo
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Oncology
Subjects:
CDK4/6 inhibitors
biomarker
thymidine kinase-1
PIK3CA
resistance
palbociclib
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00666/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00666/full

Similar Items